The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Shuzhen Liu, J. Wayne Cowens et al.|Clinical Cancer Research|2014Cited by 219
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F. Singer, Michael Gnant, Georg Pfeiler et al.|European Journal of Cancer|2020Cited by 52
Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 studyMichael Knauer, Michael Gnant, Christine Gruber et al.|Cancer Research|2015Cited by 21
Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trialJakob M. Riedl, Armin Gerger, Samantha O. Hasenleithner et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.Georg Pfeiler, Michael Gnant, Robert Königsberg et al.|Journal of Clinical Oncology|2014Cited by 7